Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2024-2028
The duchenne muscular dystrophy (DMD) therapeutics market is forecasted to grow by USD 4373.3 mn during 2023-2028, accelerating at a CAGR of 28.21% during the forecast period. The report on the duchenne muscular dystrophy (DMD) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need for duchenne muscular dystrophy therapeutics, increasing strategic alliances among the vendors, and introduction of patient assistance programs.
Technavio's duchenne muscular dystrophy (DMD) therapeutics market is segmented as below:
- By Type
- Biologics
- Small molecules
- By Distribution Channel
- Offline
- Online
- By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the strong pipeline for duchenne muscular dystrophy therapeutics as one of the prime reasons driving the duchenne muscular dystrophy (DMD) therapeutics market growth during the next few years. Also, increasing research funding for duchenne muscular dystrophy therapeutics and special drug designation for duchenne muscular dystrophy (DMD) therapeutics will lead to sizable demand in the market.
The report on the duchenne muscular dystrophy (DMD) therapeutics market covers the following areas:
- Duchenne muscular dystrophy (DMD) therapeutics market sizing
- Duchenne muscular dystrophy (DMD) therapeutics market forecast
- Duchenne muscular dystrophy (DMD) therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading duchenne muscular dystrophy (DMD) therapeutics market vendors that include BioMarin Pharmaceutical Inc., Capricor Therapeutics Inc., CRISPR Therapeutics AG, CVS Health Corp., Daiichi Sankyo Co. Ltd., Editas Medicine Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Italfarmaco Holding SPA, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., PTC Therapeutics Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., The Cleveland Clinic Foundation, Vertex Pharmaceuticals Inc., and Wave Life Sciences Ltd.. Also, the duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.